Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated H
资讯
2024-09-10
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1
Preliminary activit...